• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

CRISPR Therapeutics Is Editing Out Its Correction

Investors can now look to buy shares of this biotech firm.
By BRUCE KAMICH
Jun 14, 2021 | 12:20 PM EDT
Stocks quotes in this article: CRSP

In our last review of CRISPR Therapeutics (CRSP)  on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses." 

 
CRSP declined to a new low in early May, but has strengthened into June.
 
Let's check on the charts again.
 
In this daily bar chart of CRSP, below, we can see that prices have held above the chart support in the $90 area from July to early November. CRSP has managed to rally back above the 50-day and 200-day moving average lines. The daily On-Balance-Volume (OBV) line looks like it has been bottoming in the past three to four months. The Moving Average Convergence Divergence (MACD) oscillator gave cover-shorts buy signals in March and May and is now crossing above the zero-line for an outright-buy signal. 
 
 
In this weekly Japanese candlestick chart of CRSP, below, we see some bullish clues. There are a couple lower shadows in the $105-$90 area as traders rejected the lows. Prices are testing the underside of the 40-week moving average line and should soon close above it. The OBV line has been improving since March. The MACD oscillator has been narrowing and should cross to the upside in a few weeks.  
 
  
 
In this daily Point and Figure chart of CRSP, below, we can see a potential upside price target in the $171 area.  
 
 
In this weekly close only Point and Figure chart of CRSP, below, we can see a price target in the $211 area. 
 
 
 
 
Bottom line strategy: The correction that started back in January looks to be over, so traders could approach the long side of CRSP at current levels. Risk to $103; $171 and then $211 are our price targets for now. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Biotechnology | Healthcare

More from Investing

It Is Time for the Market to Build Support Levels and Rest

James "Rev Shark" DePorre
Aug 12, 2022 7:40 AM EDT

As the action cools, there is going to be more concern about how easy it will be for this market to continue to rally at this pace.

PPI Cools, Home Prices Don't, Fed in the Dark, Technical Battle Lines, Chevron

Stephen Guilfoyle
Aug 12, 2022 7:29 AM EDT

Just when is the Federal Reserve going to reduce the cash slosh, anyway?

Let's Update 3 Recent Trades on Meta, Gold and Bumble

Ed Ponsi
Aug 12, 2022 7:00 AM EDT

It's clean-up time.

A Win-Win for the Bulls and the Bears

Helene Meisler
Aug 12, 2022 6:00 AM EDT

Let's look at breadth on the S&P 500, the put/call ratio, the bonds, the overbought market, and more.

Making Sense of Irrational Market Moves

James "Rev Shark" DePorre
Aug 11, 2022 4:55 PM EDT

Has this recent very powerful rally created a supply of underinvested bulls who are anxious to buy pullbacks and dips?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login